Bausch Health Companies Inc. Stock price Toronto S.E.

Equities

BHC

CA0717341071

Pharmaceuticals

Market Closed - Toronto S.E. 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
14.35 CAD +0.84% Intraday chart for Bausch Health Companies Inc. +11.93% +35.00%
Sales 2024 * 9.39B 12.71B Sales 2025 * 9.21B 12.47B Capitalization 3.88B 5.25B
Net income 2024 * 220M 298M Net income 2025 * 11M 14.9M EV / Sales 2024 * 2.53 x
Net Debt 2024 * 19.91B 26.95B Net Debt 2025 * 18.33B 24.82B EV / Sales 2025 * 2.41 x
P/E ratio 2024 *
16.9 x
P/E ratio 2025 *
531 x
Employees 20,270
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.37%
More Fundamentals * Assessed data
Dynamic Chart
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Brief: Says Will Present New Scientific Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Toronto healthcare stocks rise in flat market, Canada Goose slides RE
Billionaires sought to help fund Trump bond in civil fraud case, sources say RE
Trump floats billionaire Paulson as potential Treasury chief, Bloomberg reports RE
Bausch Health's Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of Relistor MT
Bausch Health Brief: Salix Pharmaceuticals Announcing a Phase 2 Investigator-Initiated Study of RELISTOR (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma MT
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma CI
RBC Raises Bausch Health Target to US$9, After Q4 And 2024 Guidance MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating MT
TSX closes at 22-month high powered by tech rally RE
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says MT
Toronto Stocks Climb, Loblaw Shares Rise on 4Q Profit, Revenue Growth DJ
Bausch Health's Q4 Loss Narrows, Revenue Increases; Issues 2024 Revenue Outlook; Shares Gain Pre-Bell MT
Transcript : Bausch Health Companies Inc., Q4 2023 Earnings Call, Feb 22, 2024
More news
1 day+0.84%
1 week+11.93%
Current month+12.37%
1 month+14.80%
3 months+35.00%
6 months+29.05%
Current year+35.00%
More quotes
1 week
12.84
Extreme 12.84
14.62
1 month
12.23
Extreme 12.23
14.62
Current year
10.10
Extreme 10.1
14.62
1 year
7.56
Extreme 7.56
14.62
3 years
5.10
Extreme 5.1
42.45
5 years
5.10
Extreme 5.1
43.97
10 years
5.10
Extreme 5.1
347.84
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 -
Director of Finance/CFO 51 22-05-23
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 08-07-31
Chairman 68 17-05-31
Director/Board Member 35 21-03-16
More insiders
Date Price Change Volume
24-03-28 14.35 +0.84% 590,389
24-03-27 14.23 +6.19% 643,677
24-03-26 13.4 +3.96% 994,889
24-03-25 12.89 -0.92% 320,846
24-03-22 13.01 +1.48% 206,667

Delayed Quote Toronto S.E., March 28, 2024 at 04:00 pm EDT

More quotes
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
10.61 USD
Average target price
9.786 USD
Spread / Average Target
-7.77%
Consensus
  1. Stock
  2. Equities
  3. Stock Bausch Health Companies Inc.
  4. Stock Bausch Health Companies Inc. - Toronto S.E.